Recent Progress in the Development of Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase

Koch, Uwe; Narjes, Frank
July 2007
Current Topics in Medicinal Chemistry;Jul2007, Vol. 7 Issue 13, p1302
Academic Journal
The global prevalence of hepatitis C virus (HCV) infection and the serious consequences associated with the chronic state of the disease have become a worldwide health problem. A combination therapy comprising Interferon-alpha and Ribavirin represents the current standard treatment for chronic HCV infection, although it has demonstrated limited success and causes serious side effects. Promising alternative approaches toward the control of HCV infection include the development of small molecule inhibitors of viral enzymes interfering with the essential steps in the life cycle of the virus. In this review we will focus on inhibitors of the HCV-encoded NS5B RNA-dependent RNA polymerase (NS5B RdRp) which is essential for viral replication and has been recognized as a prime target for therapeutic intervention.


Related Articles

  • A siege of hepatitis: Fighting a defiant virus. Schiffer, Joshua T.; Scott, John; Corey, Lawrence // Nature Medicine;Mar2011, Vol. 17 Issue 3, p253 

    The article discusses the clinincal development to treat hepatitis C. It states that the turnover of viruses in hepatitis C infections is high and that replication of hepatitis C occurs through an RNA-dependent RNA polymerase in the cytosol. It also mentions that hepatitis C's rapid kinetics...

  • So far, so good for sofosbuvir at ISPOR.  // PharmacoEconomics & Outcomes News;Dec2014, Vol. 717 Issue 1, p35 

    The article investigates the cost-effectiveness of Sofosbuvir from Gilead Sciences for treating hepatitis C virus (HCV)-infected patients. Topics discussed include Sofosbuvir's ability to inhibit the RNA polymerase that the virus uses to replicate its RNA, the advantages of Sofosbuvir over...

  • Sofosbuvir in the Treatment of Chronic Hepatitis C: New Dog, New Tricks. Abraham, George M.; Spooner, Linda M. // Clinical Infectious Diseases;Aug2014, Vol. 59 Issue 3, p411 

    Sofosbuvir, marketed under the name Sovaldi, is the first in a new class of agents for the treatment of chronic hepatitis C. This article reviews the pharmacology, pharmacokinetics, drug interactions, clinical efficacy, and adverse effects of this new agent.The existing standard of care for...

  • De Novo Polymerase Activity and Oligomerization of Hepatitis C Virus RNA-Dependent RNA-Polymerases from Genotypes 1 to 5. Clemente-Casares, Pilar; López-Jiménez, Alberto J.; Bellón-Echeverría, Itxaso; Encinar, José Antonio; Martínez-Alfaro, Elisa; Pérez-Flores, Ricardo; Mas, Antonio // PLoS ONE;2011, Vol. 6 Issue 4, p1 

    Hepatitis C virus (HCV) shows a great geographical diversity reflected in the high number of circulating genotypes and subtypes. The response to HCV treatment is genotype specific, with the predominant genotype 1 showing the lowest rate of sustained virological response. Virally encoded enzymes...

  • Inhibitor Candidates's Identification of HCV's RNA polymerase NS5B Using Virtual Screening against iPPI-library. Sulistyawati, Indah; K. P., Sulistyo Dwi; Ichsan, Mochammad // AIP Conference Proceedings;2016, Vol. 1718 Issue 1, p1 

    Hepatitis C is one of the major causes of chronic liver failure that caused by Hepatitis C Virus (HCV). Preventing the progression of HCV's replication through the inhibition of The RNA polymerase NS5B of Hepatitis C virus (NS5B) can be achieved via 4 binding regions: Site I (Thumb I), Site II...

  • Efficient In SilicoAssay of Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase by Structure-Based Virtual Screening and In VitroEvaluation. Ying-Ting Lin; Kuo-Jung Huang; Chin-Kai Tseng; Kuan-Jen Chen; Hui-Min Wang; Jin-Ching Lee // Assay & Drug Development Technologies;Jun2011, Vol. 9 Issue 3, p290 

    AbstractTo identify a new protective or therapeutic intervention for hepatitis C virus (HCV) infection, we performed efficient structure-based virtual screening to identify novel inhibitory agents for HCV. To this end, we selected NS5B, an RNA-dependent RNA polymerase (RdRp), as the target for...

  • HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment. Sarrazin, Christoph; Manns, Michael; Calleja, Jose Luis; Garcia-Samaniego, Javier; Forns, Xavier; Kaste, Renee; Bai, Xiaofei; Wu, Jing; Stern, Jerry O. // PLoS ONE;12/28/2016, Vol. 11 Issue 12, p1 

    This study evaluated the interferon-free, oral combination of deleobuvir (non-nucleoside HCV NS5-RNA-polymerase inhibitor) and faldaprevir (HCV NS3/4A-protease inhibitor) with ribavirin in patients with HCV genotype-1b and moderate (Child-Pugh B [CPB], n = 17) or mild hepatic impairment...

  • Uncoupling RNA virus replication from transcription via the polymerase: functional and evolutionary insights. Baodong Wu; White, K. Andrew // EMBO Journal;12/26/2007, Vol. 26 Issue 24, p5120 

    Many eukaryotic positive-strand RNA viruses transcribe subgenomic (sg) mRNAs that are virus-derived messages that template the translation of a subset of viral proteins. Currently, the premature termination (PT) mechanism of sg mRNA transcription, a process thought to operate in a variety of...

  • Reconstruction of viral population structure from next-generation sequencing data using multicommodity flows. Skums, Pavel; Mancuso, Nicholas; Artyomenko, Alexander; Tork, Bassam; Mandoiu, Ion; Khudyakov, Yury; Zelikovsky, Alex // BMC Bioinformatics;2013, Vol. 14 Issue Suppl 9, p1 

    Background: Highly mutable RNA viruses exist in infected hosts as heterogeneous populations of genetically close variants known as quasispecies. Next-generation sequencing (NGS) allows for analysing a large number of viral sequences from infected patients, presenting a novel opportunity for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics